The Apex Times
Above the Noise
Business Wire
BusinessRTX reports third-quarter results above expectations, but cited risks keep investors cautiousThe Apex TimesBusinessZacks highlights Meta Platforms’ AI-and-ads push alongside Tesla’s profitability focusThe Apex TimesBusinessToyota’s Hydrogen Headquarters reports progress toward fueling upgrades for heavy-duty fuel-cell trucksThe Apex TimesBusinessSpreetail wins recognition from Walmart, TikTok Shop and Lowe’s for marketplace fulfillment performanceThe Apex TimesBusinessPepsiCo leans into seasonal comfort branding as consumers spend more time indoorsThe Apex TimesBusinessMorgan Stanley survey finds defined contribution 401(k)s are viewed as the top valued employee benefitThe Apex TimesBusinessJPMorgan expands JPM Coin onto Ethereum, raising new questions about banks’ role in cryptoThe Apex TimesBusinessBroadcom extends infrastructure agreement with FedEx to support global operationsThe Apex TimesBusinessBuffett’s Berkshire and the long-term compounding claim: a “mindset” question for today’s investorsThe Apex TimesBusinessStudy Finds Renters Are Now 37% of Recent Home Security System Buyers, Highlighting a Changing Smart Home Customer BaseThe Apex TimesBusinessApple schedules a launch event for new Pro Macs, with John Ternus tied to the product pushThe Apex TimesBusinessBank of America holds to an October Fed rate-hike view even as traders price in a smaller chanceThe Apex TimesBusinessRTX reports third-quarter results above expectations, but cited risks keep investors cautiousThe Apex TimesBusinessZacks highlights Meta Platforms’ AI-and-ads push alongside Tesla’s profitability focusThe Apex TimesBusinessToyota’s Hydrogen Headquarters reports progress toward fueling upgrades for heavy-duty fuel-cell trucksThe Apex TimesBusinessSpreetail wins recognition from Walmart, TikTok Shop and Lowe’s for marketplace fulfillment performanceThe Apex TimesBusinessPepsiCo leans into seasonal comfort branding as consumers spend more time indoorsThe Apex TimesBusinessMorgan Stanley survey finds defined contribution 401(k)s are viewed as the top valued employee benefitThe Apex TimesBusinessJPMorgan expands JPM Coin onto Ethereum, raising new questions about banks’ role in cryptoThe Apex TimesBusinessBroadcom extends infrastructure agreement with FedEx to support global operationsThe Apex TimesBusinessBuffett’s Berkshire and the long-term compounding claim: a “mindset” question for today’s investorsThe Apex TimesBusinessStudy Finds Renters Are Now 37% of Recent Home Security System Buyers, Highlighting a Changing Smart Home Customer BaseThe Apex TimesBusinessApple schedules a launch event for new Pro Macs, with John Ternus tied to the product pushThe Apex TimesBusinessBank of America holds to an October Fed rate-hike view even as traders price in a smaller chanceThe Apex TimesBusinessRTX reports third-quarter results above expectations, but cited risks keep investors cautiousThe Apex TimesBusinessZacks highlights Meta Platforms’ AI-and-ads push alongside Tesla’s profitability focusThe Apex TimesBusinessToyota’s Hydrogen Headquarters reports progress toward fueling upgrades for heavy-duty fuel-cell trucksThe Apex TimesBusinessSpreetail wins recognition from Walmart, TikTok Shop and Lowe’s for marketplace fulfillment performanceThe Apex TimesBusinessPepsiCo leans into seasonal comfort branding as consumers spend more time indoorsThe Apex TimesBusinessMorgan Stanley survey finds defined contribution 401(k)s are viewed as the top valued employee benefitThe Apex TimesBusinessJPMorgan expands JPM Coin onto Ethereum, raising new questions about banks’ role in cryptoThe Apex TimesBusinessBroadcom extends infrastructure agreement with FedEx to support global operationsThe Apex TimesBusinessBuffett’s Berkshire and the long-term compounding claim: a “mindset” question for today’s investorsThe Apex TimesBusinessStudy Finds Renters Are Now 37% of Recent Home Security System Buyers, Highlighting a Changing Smart Home Customer BaseThe Apex TimesBusinessApple schedules a launch event for new Pro Macs, with John Ternus tied to the product pushThe Apex TimesBusinessBank of America holds to an October Fed rate-hike view even as traders price in a smaller chanceThe Apex TimesBusinessRTX reports third-quarter results above expectations, but cited risks keep investors cautiousThe Apex TimesBusinessZacks highlights Meta Platforms’ AI-and-ads push alongside Tesla’s profitability focusThe Apex TimesBusinessToyota’s Hydrogen Headquarters reports progress toward fueling upgrades for heavy-duty fuel-cell trucksThe Apex TimesBusinessSpreetail wins recognition from Walmart, TikTok Shop and Lowe’s for marketplace fulfillment performanceThe Apex TimesBusinessPepsiCo leans into seasonal comfort branding as consumers spend more time indoorsThe Apex TimesBusinessMorgan Stanley survey finds defined contribution 401(k)s are viewed as the top valued employee benefitThe Apex TimesBusinessJPMorgan expands JPM Coin onto Ethereum, raising new questions about banks’ role in cryptoThe Apex TimesBusinessBroadcom extends infrastructure agreement with FedEx to support global operationsThe Apex TimesBusinessBuffett’s Berkshire and the long-term compounding claim: a “mindset” question for today’s investorsThe Apex TimesBusinessStudy Finds Renters Are Now 37% of Recent Home Security System Buyers, Highlighting a Changing Smart Home Customer BaseThe Apex TimesBusinessApple schedules a launch event for new Pro Macs, with John Ternus tied to the product pushThe Apex TimesBusinessBank of America holds to an October Fed rate-hike view even as traders price in a smaller chanceThe Apex Times
Back to front
AstraZeneca Teams Up With Oracle to Apply AI to Clinical Research
The Apex Times

THE APEX TIMES

Business/The Apex Times/Oct 20, 8:28 AM EDT

AstraZeneca Teams Up With Oracle to Apply AI to Clinical Research

The drugmaker said it is working with Oracle to improve how clinical research is planned and conducted, pointing to the growing role of artificial intelligence in pharmaceutical development.

By The Apex Times Newsroom2 min readAI-assisted Apex article

AstraZeneca has entered a new artificial-intelligence partnership with Oracle, aiming to refine parts of its clinical research workflow, according to a report citing the companies’ collaboration.

The announcement, reported by The Wall Street Journal, frames the effort as an effort to use AI to improve the clinical research process. The companies did not, in the report, spell out the specific systems being used, the datasets involved, or the clinical stages that will benefit first.

While details were limited, the move indicates how pharmaceutical companies are increasingly turning to technology vendors to try to compress timelines and reduce operational friction across drug development. Clinical research is resource-intensive, involving study design work, site and patient recruitment, data capture, and ongoing monitoring as trials progress.

For Oracle, the collaboration fits into a broader pattern in which large enterprise technology providers seek roles in the health and life sciences segment through cloud, data infrastructure, and analytics. In this case, the reported focus is not on commercial software for consumer markets but on improving the mechanics of clinical studies.

For AstraZeneca, the potential payoff of AI in clinical research typically centers on speed and quality of decision-making, including helping teams make more informed assumptions during study planning and improving how information is processed during trials. Even when AI does not replace clinical judgment, it can be used to handle large volumes of trial data and operational inputs.

Still, the partnership leaves open key questions. The report did not provide metrics for expected performance gains, timelines for deployment, or whether the work is aimed at early discovery, late-stage trials, or post-trial analysis. It also did not describe any regulatory validation approach, such as whether AI-assisted outputs will be reviewed under the company’s existing clinical governance processes.

In the pharmaceutical sector, AI projects have often faced scrutiny around data quality, bias, transparency, and reproducibility. Without further disclosure, it is unclear how AstraZeneca and Oracle will address those issues, particularly for decisions that may affect trial outcomes or participant safety.

What to watch next is whether the companies provide additional specifics, such as which therapeutic areas or trial programs are included, what role Oracle’s technology will play, and any stated milestones for rolling out the tools across clinical teams. Another point of interest will be whether AstraZeneca describes how AI outputs will be verified and documented for regulatory and audit purposes.

Why It Matters

  • Partnerships like this reflect the competitive push to apply AI across drug development, where operational complexity is high.
  • The deal underscores the growing involvement of enterprise technology vendors in life sciences beyond traditional IT roles.
  • Clinical research is heavily scrutinized for safety and data integrity, so the next disclosures on validation and documentation could influence how other companies approach AI adoption.
  • Investors and industry watchers may look for evidence that AI can reduce delays or improve trial execution without compromising regulatory expectations.

Sources

Key Facts

  • AstraZeneca is partnering with Oracle to refine clinical research using artificial intelligence.
  • The collaboration was reported by The Wall Street Journal.
  • The report did not specify which clinical trial stages or workflows will be included first.
  • The report did not disclose performance targets, timelines, or measurable outcomes.
  • No details were provided on the technical implementation, data sources, or governance and validation approach for AI in clinical settings.

Technology Related

Oct 20, 9:29 AM EDT
The Apex Times

Zacks highlights Meta Platforms’ AI-and-ads push alongside Tesla’s profitability focus

A Zacks Investment Ideas feature roundup points to Meta Platforms’ quarterly performance and its AI ambitions through products such as Muse AI, while also flagging Tesla’s vehicle profitability theme and ongoing innovation efforts. The feature, published via Yahoo Finance, frames both companies as markets look closely at spending discipline and tangible returns.

Zacks highlights Meta Platforms’ AI-and-ads push alongside Tesla’s profitability focus
The Apex Times
Oct 20, 9:18 AM EDT
The Apex Times

Informatica Adds Nearly $456 Million to Salesforce’s Q2 Fiscal 2027 Revenue, Strengthening the Data-and-AI Pitch

A reported $456 million contribution from Informatica into Salesforce’s second quarter of fiscal 2027 highlights how the CRM giant is bundling data management and artificial intelligence to extend its platform advantage. The question for investors and customers is whether the gains translate into durable demand across Salesforce’s core software and services.

Informatica Adds Nearly $456 Million to Salesforce’s Q2 Fiscal 2027 Revenue, Strengthening the Data-and-AI Pitch
The Apex Times
AstraZeneca Teams Up With Oracle to Apply AI to Clinical Research | The Apex Times